1. Home
  2. CUE vs LYEL Comparison

CUE vs LYEL Comparison

Compare CUE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$4.59

Market Cap

177.0M

Sector

Health Care

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$13.56

Market Cap

195.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CUE
LYEL
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.0M
195.8M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CUE
LYEL
Price
$4.59
$13.56
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
★ $68.67
$37.63
AVG Volume (30 Days)
★ 552.6K
208.9K
Earning Date
11-16-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.11
N/A
EPS
N/A
★ N/A
Revenue
★ $27,466,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 195.75
N/A
52 Week Low
$0.17
$7.20
52 Week High
$45.50
$45.00

Technical Indicators

Market Signals
Indicator
CUE
LYEL
Relative Strength Index (RSI) 24.71 53.58
Support Level $0.22 $12.25
Resistance Level $33.95 $14.97
Average True Range (ATR) 2.75 1.66
MACD -1.47 -0.12
Stochastic Oscillator 8.18 41.29

Price Performance

Historical Comparison
CUE
LYEL

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: